eli lilly cease and desist letter tirzepatide The FDA has issued warning letters to multiple companies marketing compounded Retatrutide, an investigational drug from still in Phase II trials. While early studies have shown promising weight-loss results, Retatrutide Eli Lilly strikes Zepbound deal

Impact on weight tracking Early dosing can create confusing weight fluctuations in the days following the compressed dose

A lower-concentration build (2.5 mg/mL) spreads the dose across more units, so a one- or two-unit error is proportionally smaller at the cost of multi-fill draws later

Nausea is the most frequently reported effect, occurring in roughly 12 to 18% of people at the starting dose based on trial data

Retatrutide might result in more frequent or severe gastrointestinal side effects, including nausea and diarrhea, than tirzepatide

Unopened tirzepatide pens should be stored in the refrigerator at 36F to 46F (2C to 8C) in their original carton to protect from light

This slower digestion helps prevent blood sugar spikes, which can worsen insulin resistance